Gabapentin Suspension
Product Images NDC 59762-5050
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 59762-5050). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Gabapentin Structural Formula (Image 02)
Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Image 03)
Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Image 04)
Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Image 05)
Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Image 06)
Gabapentin Oral Solution 250 mg Per 5 mLcarton Label (Image 07)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.